Avandia Sales Expected To Decline Despite FDA Reprieve

The US Food and Drug Administration (FDA) has decided to allow continued availability of Avandia (rosiglitazone), one of GlaxoSmithKline (GSK)'s best selling drugs in the US. The safety of the type 2 diabetes drug has been disputed since 2007 when a clinical study from a US cardiologist suggested it caused an increased risk of cardiovascular events, especially for patients also receiving nitrate drugs or

To read the full article, please choose one of the following options: